UK – Masters Speciality Pharma is pleased to announce a partnership agreement with Speciality European Pharma (SEP) for the exclusive distribution of Mitocin®/Mitem® (mitomycin) to the Caribbean, Egypt, Kuwait, Iran, Saudi Arabia, UAE, Kenya, Seychelles, Uganda, Zimbabwe, Chile, Denmark, Greece, Ireland, Norway and Sweden.
Masters has 30 years experience in the ethical and compliant supply of drugs to countries where an unmet need for the medication exists. Our regulatory knowledge, licensure and logistics capabilities will ensure that patients requiring treatment with Mitocin®/Mitem® (mitomycin) have access to this important medication.
Rakesh Tailor, Speciality European Pharma’s General Manager for Northern Europe said “Having worked with Masters for a number of years we are delighted to have cemented this partnership through formal agreement. This arrangement hopefully signals the continuum of a long and successful business relationship.”
Mitocin®/Mitem® (mitomycin) is a cytotoxic medicine used in the treatment of a variety of cancers, including bladder cancer, and although the product has been on the market for many years it remains the treatment of choice for many patients with superficial risk bladder cancer.
Heather Gamble, Masters Business Marketing Director said “Entering into exclusive partnership with Specialty European Pharma allows us to focus our resources on the territories where we have been granted exclusive distribution, this will help to ensure medication reaches those patients requiring treatment with mitomycin.”
In order to obtain access to Mitocin®/Mitem® (mitomycin) patients or healthcare professionals should contact: Masters Speciality Pharma Email: orders@masters-sp.com Phone: +44 (0)208 327 0900 Fax: +44 (0)208 327 0901 or Online: www.masters-sp.com
- Ends-
For information and interview requests please contact, Lorna Wright, Marketing Communications Manager, on E: lorna.wright@masters-sp.com or T: +44 (0)208 327 0900
About Masters Speciality Pharma
Masters Speciality Pharma is an international healthcare company, headquartered in the UK, licensed for the international procurement and compliant supply of a comprehensive range of specialty medicines, including controlled drugs. Established in 1984, our expertise and capabilities rest in the worldwide legal importation of innovative pharmaceuticals that are unlicensed, discontinued, are in short supply or orphan drugs for rare diseases, for supply into countries where they are unregistered or awaiting approval, which are ethically sourced through partnerships with a number of world leading pharmaceutical companies.
Masters Speciality Pharma has commercial operations and accredited warehousing in South America, Central America, Europe and the USA. Its multilingual customer services specialists and high performing management teams are led by a strong Executive team and distinguished Board.
For more information about Masters Speciality Pharma, please visit www.masters-sp.com
Mitocin®/Mitem® (mitomycin)
Mitocin® is a cytostatic injectable mitomycin product used in the treatment of a range of cancers. Most notably, Mitocin® is given intravesically (in the bladder) for the treatment of non-muscle invasive bladder cancer.
About Speciality European Pharma (SEP)
Speciality European Pharma’s goal is to become Europe’s leading specialist urology focused pharmaceutical company by developing and commercialising its existing product portfolio and through further acquisitions and licensing. SEP aims to be considered the partner of choice for companies seeking to register and market their urology products in Europe.
For more information about Speciality European Pharma, please visit www.specialityeuropeanpharma.com
Help employers find you! Check out all the jobs and post your resume.
